Intermittent Fasting Alleviates Non‐Alcoholic Steatohepatitis by Regulating Bile Acid Metabolism and Promoting Fecal Bile Acid Excretion in High‐Fat and High‐Cholesterol Diet Fed Mice

Abstract

ScopeIntermittent fasting (IF) has a protective role across a wide range of chronic disorders, including obesity, diabetes, and cardiovascular disease, but its protection against non‐alcoholic steatohepatitis (NASH) is still lacking. This study seeks to investigate how IF alleviates NASH by regulating gut microbiota and bile acids (BAs) composition.Methods and resultsMale C57BL/6 mice are fed a high‐fat and high‐cholesterol (HFHC) diet for 16 weeks to establish a NASH model. Mice then continued HFHC feeding and are treated with or without every other day fasting for 10 weeks. Hepatic pathology is assessed using hematoxylin‐eosin staining. Gut microbiota of the cecum are profiled using 16S rDNA gene sequencing and the levels of BAs in serum, colon contents, and feces are measured using ultra‐performance liquid chromatography‐tandem mass spectrometry. Results indicate that IF significantly decreases murine body weight, insulin resistance, hepatic steatosis, ballooning, and lobular inflammation. IF reshapes the gut microbiota, reduces the accumulation of serum BAs, and increases total colonic and fecal BAs. Moreover, IF increases the expression of cholesterol 7α‐hydroxylase 1 in liver, but decreases the expressions of both farnesoid‐X‐receptor and fibroblast growth factor 15 in the ileum.ConclusionIF alleviates NASH by regulating bile acid metabolism and promoting fecal bile acid excretion.